The estimated Net Worth of Philip Ashman is at least $723 Tausend dollars as of 8 April 2021. Philip Ashman owns over 45 units of Alimera Sciences stock worth over $107,166 and over the last 12 years he sold ALIM stock worth over $62,398. In addition, he makes $553,179 as Chief Operating Officer und Senior Vice President - Commercial Operations Europe at Alimera Sciences.
Philip has made over 4 trades of the Alimera Sciences stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 45 units of ALIM stock worth $433 on 8 April 2021.
The largest trade he's ever made was selling 25,500 units of Alimera Sciences stock on 18 January 2018 worth over $30,600. On average, Philip trades about 2,014 units every 45 days since 2013. As of 8 April 2021 he still owns at least 19,379 units of Alimera Sciences stock.
You can see the complete history of Philip Ashman stock trades at the bottom of the page.
Dr. Philip Ashman Ph.D. serves as Chief Operating Officer, Senior Vice President - Commercial Operations Europe of the Company. He has served as Chief Operating Officer and Senior Vice President Commercial Operations Europe since January 2019. Previously, Dr. Ashman served as the Senior Vice President, Managing Director Europe since January 2013. Prior to joining us, Dr. Ashman held a number of leadership roles at Bayer from 2006 to 2012, including being responsible for leadership of the market access strategy in the U.K. for Bayer, covering all therapy areas including ophthalmology. Prior to this, Dr. Ashman served as Vice President Global Marketing Oncology at Bayer and also as Vice President Regional Business Unit Head (Europe) Oncology, responsible for the delivery of oncology sales and profitability targets in Europe, Canada, the Middle East and Africa. Before 2006, Dr. Ashman held UK-based business leadership positions in AstraZeneca and Sanofi. Dr. Ashman holds a doctorate in biochemistry from the University of London: Royal Holloway and Bedford, U.K., and a Bachelor of Science degree in biochemistry from the University College London, U.K.
As the Chief Operating Officer und Senior Vice President - Commercial Operations Europe of Alimera Sciences, the total compensation of Philip Ashman at Alimera Sciences is $553,179. There are 4 executives at Alimera Sciences getting paid more, with Richard Eiswirth having the highest compensation of $977,025.
Philip Ashman is 55, he's been the Chief Operating Officer und Senior Vice President - Commercial Operations Europe of Alimera Sciences since 2019. There are 11 older and 4 younger executives at Alimera Sciences. The oldest executive at Alimera Sciences Inc. is James Largent, 70, who is the Lead Independent Director.
Philip's mailing address filed with the SEC is 6310 TOWN SQUARE, SUITE 400, , ALPHARETTA, GA, 30005.
Over the last 15 years, insiders at Alimera Sciences have traded over $14,704,529 worth of Alimera Sciences stock and bought 8,598,915 units worth $59,337,384 . The most active insiders traders include Capital, Llc Armistice Capi..., Nicole Vitullo und Jesse I Treu. On average, Alimera Sciences executives and independent directors trade stock every 32 days with the average trade being worth of $468,137. The most recent stock trade was executed by Partners Lpjohnson David Ed... on 14 September 2023, trading 579,000 units of ALIM stock currently worth $1,962,810.
alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.
Alimera Sciences executives and other stock owners filed with the SEC include: